相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Sodium-Glucose Cotransporter 2 Inhibitors for Type 2 Diabetes A Systematic Review and Meta-analysis
Despoina Vasilakou et al.
ANNALS OF INTERNAL MEDICINE (2013)
Dapagliflozin add-on to metformin in type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled 102-week trial
Clifford J. Bailey et al.
BMC MEDICINE (2013)
Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30-50% of Filtered Glucose Load in Humans
Muhammad A. Abdul-Ghani et al.
DIABETES (2013)
Long-Term Safety and Efficacy of Empagliflozin, Sitagliptin, and Metformin An active-controlled, parallel-group, randomized, 78-week open-label extension study in patients with type 2 diabetes
Ele Ferrannini et al.
DIABETES CARE (2013)
Efficacy and safety of canagliflozin in Japanese patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, 12-week study
N. Inagaki et al.
DIABETES OBESITY & METABOLISM (2013)
Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise
K. Stenlof et al.
DIABETES OBESITY & METABOLISM (2013)
Efficacy and safety of canagliflozin compared with placebo and sitagliptin in patients with type 2 diabetes on background metformin monotherapy: a randomised trial
F. J. Lavalle-Gonzalez et al.
DIABETOLOGIA (2013)
Inhibition of Renal Glucose Reabsorption: A Novel Strategy for Achieving Glucose Control in Type 2 Diabetes Mellitus
Muhammad Abdul-Ghani et al.
Endocrine Practice (2013)
Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial
William T. Cefalu et al.
LANCET (2013)
Ipragliflozin and other sodium-glucose cotransporter-2 (SGLT2) inhibitors in the treatment of type 2 diabetes: Preclinical and clinical data
Eiji Kurosaki et al.
PHARMACOLOGY & THERAPEUTICS (2013)
The Clinical Efficacy and Safety of Sodium Glucose Cotransporter-2 Inhibitors in Adults with Type 2 Diabetes Mellitus
Shawn Riser Taylor et al.
PHARMACOTHERAPY (2013)
Canagliflozin: a novel treatment option for type 2 diabetes
Eric Dietrich et al.
DRUG DESIGN DEVELOPMENT AND THERAPY (2013)
Long-Term Efficacy of Dapagliflozin in Patients With Type 2 Diabetes Mellitus Receiving High Doses of Insulin A Randomized Trial
John P. H. Wilding et al.
ANNALS OF INTERNAL MEDICINE (2012)
LX4211, a Dual SGLT1/SGLT2 Inhibitor, Improved Glycemic Control in Patients With Type 2 Diabetes in a Randomized, Placebo-Controlled Trial
B. Zambrowicz et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Effect of canagliflozin, a sodium glucose co-transporter 2 (SGLT2) inhibitor, on bacteriuria and urinary tract infection in subjects with type 2 diabetes enrolled in a 12-week, phase 2 study
L. E. Nicolle et al.
CURRENT MEDICAL RESEARCH AND OPINION (2012)
Na+-D-glucose Cotransporter SGLT1 is Pivotal for Intestinal Glucose-Absorption and Glucose-Dependent Incretin Secretion
Valentin Gorboulev et al.
DIABETES (2012)
Effects of Dapagliflozin, an SGLT2 Inhibitor, on HbA1c, Body Weight, and Hypoglycemia Risk in Patients With Type 2 Diabetes Inadequately Controlled on Pioglitazone Monotherapy
Julio Rosenstock et al.
DIABETES CARE (2012)
Empagliflozin, a novel selective sodium glucose cotransporter-2 (SGLT-2) inhibitor: characterisation and comparison with other SGLT-2 inhibitors
R. Grempler et al.
DIABETES OBESITY & METABOLISM (2012)
Empagliflozin, a novel potent and selective SGLT-2 inhibitor, improves glycaemic control alone and in combination with insulin in streptozotocin-induced diabetic rats, a model of type 1 diabetes mellitus
G. Luippold et al.
DIABETES OBESITY & METABOLISM (2012)
Discovery of Tofogliflozin, a Novel C-Arylglucoside with an O-Spiroketal Ring System, as a Highly Selective Sodium Glucose Cotransporter 2 (SGLT2) Inhibitor for the Treatment of Type 2 Diabetes
Yoshihito Ohtake et al.
JOURNAL OF MEDICINAL CHEMISTRY (2012)
FDA rejects novel diabetes drug over safety fears
Talha Khan Burki
LANCET (2012)
Pharmacological profile of ipragliflozin (ASP1941), a novel selective SGLT2 inhibitor, in vitro and in vivo
Atsuo Tahara et al.
NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY (2012)
Effect of Canagliflozin on Renal Threshold for Glucose, Glycemia, and Body Weight in Normal and Diabetic Animal Models
Yin Liang et al.
PLOS ONE (2012)
Role of sodium-glucose transporters in glucose uptake of the intestine and kidney
Norio Harada et al.
JOURNAL OF DIABETES INVESTIGATION (2012)
Systematic review of SGLT2 receptor inhibitors in dual or triple therapy in type 2 diabetes
Christine Clar et al.
BMJ OPEN (2012)
Tofogliflozin, a Potent and Highly Specific Sodium/Glucose Cotransporter 2 Inhibitor, Improves Glycemic Control in Diabetic Rats and Mice
Masayuki Suzuki et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2012)
Learning From Glycosuria
Ele Ferrannini
DIABETES (2011)
Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin A randomized, 52-week, double-blind, active-controlled noninferiority trial
Michael A. Nauck et al.
DIABETES CARE (2011)
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with glimepiride: a randomized, 24-week, double-blind, placebo-controlled trial
K. Strojek et al.
DIABETES OBESITY & METABOLISM (2011)
SGLT2 Mediates Glucose Reabsorption in the Early Proximal Tubule
Volker Vallon et al.
JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY (2011)
Effect of kidney disease on glucose handling (including genetic defects)
Joaquim Calado et al.
KIDNEY INTERNATIONAL (2011)
Management of type 2 diabetes: new and future developments in treatment
Abd A. Tahrani et al.
LANCET (2011)
National, regional, and global trends in fasting plasma glucose and diabetes prevalence since 1980: systematic analysis of health examination surveys and epidemiological studies with 370 country-years and 2.7 million participants
Goodarz Danaei et al.
LANCET (2011)
Biology of Human Sodium Glucose Transporters
Ernest M. Wright et al.
PHYSIOLOGICAL REVIEWS (2011)
Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise A randomized, double-blind, placebo-controlled, phase 3 trial
Ele Ferrannini et al.
DIABETES CARE (2010)
Dapagliflozin treatment in patients with different stages of type 2 diabetes mellitus: effects on glycaemic control and body weight
L. Zhang et al.
DIABETES OBESITY & METABOLISM (2010)
(1S)-1,5-Anhydro-1-[5-(4-ethoxybenzyl)-2-methoxy-4-methylphenyl]-1-thio-D-glucitol (TS-071) is a Potent, Selective Sodium-Dependent Glucose Cotransporter 2 (SGLT2) Inhibitor for Type 2 Diabetes Treatment
Hiroyuki Kakinuma et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Effect of dapagliflozin in patients with type 2 diabetes who have inadequate glycaemic control with metformin: a randomised, double-blind, placebo-controlled trial
Clifford J. Bailey et al.
LANCET (2010)
Epigenetic phenomena linked to diabetic complications
Luciano Pirola et al.
NATURE REVIEWS ENDOCRINOLOGY (2010)
Quantitative PCR tissue expression profiling of the human SGLT2 gene and related family members
Jian Chen et al.
Diabetes Therapy (2010)
Renal sodium-glucose transport: role in diabetes mellitus and potential clinical implications
George L. Bakris et al.
KIDNEY INTERNATIONAL (2009)
Prevalence, treatment, and control of diagnosed diabetes in the US National Health and Nutrition Examination Survey 1999-2004
Kwok Leung Ong et al.
ANNALS OF EPIDEMIOLOGY (2008)
Dapagliflozin, a selective SGLT2 inhibitor, improves glucose homeostasis in normal and diabetic rats
Songping Han et al.
DIABETES (2008)
10-year follow-up of intensive glucose control in type 2 diabetes
Rury R. Holman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Human obesity and insulin resistance: lessons from experiments of Nature
S. O'Rahilly
BIOCHEMICAL SOCIETY TRANSACTIONS (2007)
Islet β cell failure in type 2 diabetes
Marc Prentki et al.
JOURNAL OF CLINICAL INVESTIGATION (2006)
Glucose transporters in human renal proximal tubular cells isolated from the urine of patients with non-insulin-dependent diabetes
H Rahmoune et al.
DIABETES (2005)
Phlorizin: a review
JRL Ehrenkranz et al.
DIABETES-METABOLISM RESEARCH AND REVIEWS (2005)
Insulin secretion capacity in the development from normal glucose tolerance to type 2 diabetes
M Fukushima et al.
DIABETES RESEARCH AND CLINICAL PRACTICE (2004)
Autosomal recessive renal glucosuria attributable to a mutation in the sodium glucose cotransporter (SGLT2)
LP van den Heuvel et al.
HUMAN GENETICS (2002)
Improved diabetic syndrome in C57BL/KsJ-db/db mice by oral administration of the Na+-glucose cotransporter inhibitor T-1095
K Arakawa et al.
BRITISH JOURNAL OF PHARMACOLOGY (2001)
Correction of hyperglycemia and insulin sensitivity by T-1095, an inhibitor of renal Na+-glucose cotransporters, in streptozotocin-induced diabetic rats
A Oku et al.
JAPANESE JOURNAL OF PHARMACOLOGY (2000)